Sleep Disorders Trial, Recruiting NCT06047353 Sponsor: University of Miami Condition: Sleep Disorders
Back to Sleep Disorders

Sleep Disorders Trial, Recruiting

NCT06047353
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older
  • You have been diagnosed with moderate-to-severe obstructive sleep apnea (OSA), which means you stop breathing frequently during sleep
  • You are able to attend the required study visits and sessions
  • You have reliable access to a phone

Who may not be able to join:

  • You have previously used or are currently using a PAP breathing machine or another treatment (such as a mouth device) for your sleep apnea
  • You have had surgery on your upper airway (throat or nose area) to treat sleep apnea
  • You have moderate to severe insomnia (serious ongoing difficulty falling or staying asleep)
  • You work as a commercial driver
  • You use a special type of PAP machine called adaptive servo-ventilation or bi-level positive airway pressure (confirm with trial site)
  • You have been in a car accident or a near-miss accident caused by sleepiness in the past two years
  • You have certain unstable health conditions, such as uncontrolled chest pain, heart failure, uncontrolled high blood pressure, severe lung disease, cancer, or an active mental health condition like major depression
  • You have another sleep disorder, such as a circadian rhythm disorder (a condition affecting your body clock)
  • You use extra oxygen at any time, whether awake or asleep
  • Your sleep test showed a specific type of breathing problem during sleep, such as central sleep apnea, obesity hypoventilation syndrome, or Cheyne-Stokes respiration (confirm with trial site)
  • Your blood oxygen level while awake and at rest is below 90%
  • You are currently taking part in another clinical trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Naresh Punjabi, University of Miami

Phone: 305-243-6388

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
29 September 2023
Est. completion
1 December 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of hours patient adhered to PAP therapy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov